__full__: Juq-158

The authors formalize three notions of fairness (demographic parity, equalized odds, and predictive parity) and prove that any non‑trivial classifier that satisfies two of them simultaneously must sacrifice some predictive power unless the underlying data distribution already satisfies certain symmetry properties. They also show that, under a “group‑wise calibrated” assumption, one can achieve a Pareto‑optimal frontier where small fairness gains come at negligible accuracy loss. The paper ends with a “design checklist” for practitioners: (1) Diagnose the data‑generation process, (2) Choose fairness metrics aligned with the decision context, (3) Run a sensitivity analysis on the accuracy–fairness curve.

Summarize the main points and reiterate the importance of understanding JUQ-158. JUQ-158

This document is intended for informational and educational purposes only. It does not constitute medical, legal, or safety advice, and it is not a recommendation for any kind of use. If you are a researcher, always follow institutional, local, and national regulations regarding controlled substances, novel chemicals, and laboratory safety. The authors formalize three notions of fairness (demographic

If you meant something else—such as a product code for electronics, a book, a research paper, or a different reference—could you please clarify? I’d be happy to help with that instead. Summarize the main points and reiterate the importance

Fans often share screenshots or reviews on platforms like X (formerly Twitter) or dedicated forums, driving search volume.

| Endpoint | Findings | Remarks | |----------|----------|---------| | | 120 mg kg⁻¹ | Comparable to many synthetic stimulants; indicates a relatively narrow therapeutic index. | | Cardiovascular effects | Dose‑dependent tachycardia (↑ 30‑70 bpm) and mild hypertension (↑ 10‑20 mmHg) in rats. | Consistent with DAT inhibition. | | Neurobehavioral | At 10 mg kg⁻¹ (i.p.) mice displayed head‑twitch response (a proxy for 5‑HT₂A activation) and increased locomotor activity. | Suggests combined stimulant/psychedelic profile. | | Cytotoxicity (in vitro) | IC₅₀ ≈ 30 µM in HepG2 cells (MTT assay). | Modest cytotoxicity at concentrations far above expected plasma levels. | | Genotoxicity | Negative Ames test (TA98/TA100) and mouse micronucleus assay. | No evident mutagenic risk in standard screens. | | Dependence liability | No published self‑administration or conditioned place‑preference data. | The DAT component raises theoretical abuse potential; formal studies are pending. |